Adverse cutaneous reactions to skin care products on the face vary with age, but not with sex.

BACKGROUND: Adverse skin reactions to skin care products have been increasing in recent years. However, to date, these reactions have not been well characterized. OBJECTIVE: To describe the symptoms, clinical signs and frequency of adverse cutaneous reactions to skin care products on the face in males vs females of various ages. PATIENTS AND METHODS: All outpatients diagnosed with adverse cutaneous reactions to skin care products on the face examined by dermatologists at the Dermatology Hospital of South Medical University between November 1, 2016 and October 31, 2017, employing a questionnaire and an interview, were eligible. The associations of adverse cutaneous reactions with age and sex were analysed. RESULTS: A total of 433 outpatients, accounting for 0.12% of all outpatients, were assessed. Of these, 223 patients, including 204 females and 19 males, aged 4 to 75 years, were eventually diagnosed with adverse reactions to skin care products on the face. Eighty-two per cent of patients experienced pruritus, 80% showed erythema, and 48% showed visible swelling. The incidence rates of both xerosis and oedema correlated positively with age, whereas acne-like lesions were negatively associated with age, but not with sex. CONCLUSIONS: Our results indicate that pruritus, xerosis and erythema are common adverse cutaneous reactions to facial skin care products. These reactions vary with age, but not with sex. Vigorous safety testing should precede the marketing of skin care products.

[Combination of multiple displacement amplification with short tandem repeat polymorphismin preimplantation genetic diagnosis].

OBJECTIVE: To explore the application of multiple displacement amplification (MDA) combined with short tandem repeats (STRs) in preimplantation genetic diagnosis (PGD). METHODS: MDA was applied to amplify the whole genome of a single cell and to retrieve and assemble the highly heterogeneous STR loci among human population. Haplotype analytic system was established with aiming at diagnosis of the single gene diseases by selecting the STR loci located within the pathogenic genes or on both bounding sides of the pathogenic genes. At the same time, allele specific amplification, PCR-reverse dot-blotting hybridization methods and gene sequencing methods were employed for direct detection of the pathogenic genes. The STR loci located at related chromosomes were selected to carry out allele number analysis on the basis of chromosome number and structural abnormality. RESULTS: In the study, 12 PGD systems were set up including 6 different monogenic diseases (spinal muscular atrophy, Duchenne muscular dystrophy, X-linked chronic granulomatous disease, osteopetrosis, achondroplasia, X-linked severe combined immunodeficiency), Robertsonian translocations, α-thalassemia combined with Robertsonian translocation, α- and ß-double thalassemia, ß-thalassemia with HLA typing and DMD with HLA typing. Then 44 PGD cycles were performed for 35 couples with different kinds of inherited diseases, which resulted in 20 healthy liveborns (12 singletons and 4 twins) and 5 ongoing pregnancies. The clinical pregnancy rate was 47.7% (21/44) per PGD cycle. The overall diagnostic rate was 94.6% (367/388). The MDA failed in 3.6% (14/388) single blastomeres. The amplification rate of the subsequent PCR was 97.1% and the average allele drop out (ADO) rate was 12.6% (range: 0-47.5%). CONCLUSION: The application of MDA combined with STRs provided a generic PGD approach for different genetic disorders, especially for simultaneous diagnosis of two or more hereditary statuses. The method could greatly shorten the time of developing PGD system of new diseases, which broadens the indications of PGD.

Preliminary investigation of the impact of anticentromere antibody on oocyte maturation and embryo cleavage.

OBJECTIVE: To explore whether anticentromere antibody (ACA) is the most significant antibody among antinuclear antibodies (ANA), which adversely affect oocyte maturation, embryo cleavage, and pregnancy outcome in women undergoing an intracytoplasmic sperm injection program. DESIGN: Retrospective, nested case-control study. SETTING: Center for reproductive medicine, university hospital. PATIENT(S): A total of 187 women receiving the first intracytoplasmic sperm injection cycle were enrolled in this study, including 20 women with positive ACA and ANA (ACA[+]/ANA[+] group), 51 women with negative ACA and positive ANA(ACA[-]/ANA[+] group), and 116 patients with negative ACA and ANA (ACA[-]/ANA[-] group). Patients in the three groups were age-matched. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Percentages of germinal vesicle, metaphase I, and metaphase II oocytes, embryo cleavage rate, number of high-quality embryos, and rates of pregnancy and implantation. RESULT(S): The metaphase I oocyte percentage was markedly higher and the metaphase II oocyte percentage and the normal cleavage rate were significantly lower in the ACA[+]/ANA[+] group as compared with the ACA[-]/ANA[+] group. Furthermore, statistically significant differences were found in rates of pregnancy and implantation among the three groups. However, no significant difference was found between any two groups owing to the small sample size, except for a significantly lower implantation rate being found in the ACA[+]/ANA[+] group when compared with the ACA[-]/ANA[-] group. CONCLUSION(S): Our data suggest that ACA may be the essential marker for defective oocytes or embryos in infertile women with any type of ANA.

A further exploration of the impact of antinuclear antibodies on in vitro fertilization-embryo transfer outcome.

OBJECTIVE: To determine the presence of antinuclear antibodies (ANAs) in follicular fluid (FF) and embryos as to their potential impact on IVF outcome. METHODS: A total of 100 women presenting to IVF/ICSI program were recruited in this study, wherein 50 women sero-positive for ANA served as study group (ANA+ group) and 50 women seronegative for ANA served as control group (ANA- group), and patients were age-matched in the two groups. ANA level in serum and FF were examined by ELISA, and immunofluorescence assay was employed to detect IgG within embryos. RESULTS: In ANA+ group, 36 women showed positive ANA both in serum and FF on the day of ovum pick-up (OPU), wherein 34 exhibited fluorescence of IgG in embryos. All the 50 women in control group showed negative results in serum and FF ANA on OPU day and in embryo immunofluorescence. Serum ANA level positively correlated with FF ANA level. IVF outcomes were significantly poorer in ANA+ group, mainly reflecting the less number of high-quality embryos, reduced rates of pregnancy, clinical pregnancy, and implantation. CONCLUSION: These data demonstrated the existence of ANA in FF and embryos, which may exert detrimental impact on IVF outcome.

A retrospective study on IVF outcome in patients with anticardiolipin antibody: effects of methylprednisolone plus low-dose aspirin adjuvant treatment.

Patients undergoing in vitro fertilization-embryo transfer have a high prevalence of anticardiolipin antibody (ACA). However, the relationship between ACA and IVF outcome is still controversial. The aim of the present study was to evaluate the potential effect of anticardiolipin antibody on IVF outcome and determine the role of adjuvant treatment in these ACA positive patients. The study included a total of 116 infertile women (116 IVF-ET cycles) positive for ACA, including 56 women pretreated with methylprednisolone plus low-dose aspirin before IVF (treated ACA+ group) and 60 patients without treatment (untreated ACA+ group). In addition, 518 infertile women (518 IVF-ET cycles) negative for ACA were enroled as controls (ACA- group). The results show that ACA+ patients who did not receive any adjuvant treatment showed a significantly lower fertilization rate, less high-quality embryos, as well as a markedly lower pregnancy rate and implantation rate than controls. Moreover, ACA+ patients who received methylprednisolone plus aspirin achieved significantly higher fertilization, pregnancy and implantation rates than untreated ACA+ patients (FR 69.0%, PR 46.4% and IR 25.4% vs. FR 60.0%, PR 33.3% and IR 17.9%, respectively). The overall IVF results in the treated ACA+ group were comparable to patients negative for ACA (PR 53.9% and IR 32.3%). Thus, while the presence of ACA exerts a detrimental effect on IVF outcome, ACA+ patients have a better outcome if given methylprednisolone for immunosuppression and low-dose aspirin as an anti-thrombotic agent.

Comparison of Endocrine Profile and In Vitro Fertilization Outcome in Patients with PCOS, Ovulatory PCO, or Normal Ovaries.

Aim. To compare the basic endocrine profile and outcomes of in vitro fertilization (IVF) in women with polycystic ovary syndrome (PCOS), ovulatory polycystic ovaries (PCO), or normal ovaries (NO). Methods. The basic clinical features and in vitro fertilization and embryo transfer outcome in patients receiving IVF or intracytoplasmic sperm injection (ICSI) were retrospectively analyzed. Results. The body mass index, basal luteinizing hormone, and testosterone levels were significantly lower in patients with ovulatory PCO compared to those in patients with PCOS. The PCOS patients exhibited the shortest duration of ovarian stimulation and lowest dose of gonadotropin, followed by the ovulatory PCO and NO patients. The ovulatory PCO and PCOS patients showed similar levels of E2 on the human chorionic gonadotropin treatment day and numbers of oocytes, which were both significantly higher than those of the NO patients. The fertilization rate of the PCOS patients was significantly lower than the other two groups. Compared to NO patients, the cleavage rate was lower in both PCOS and ovulatory PCO patients, however, the number of available embryos was significantly more in these two groups. The incidence of the moderate to severe ovarian hyperstimulation syndrome (OHSS) was markedly higher in the PCOS and ovulatory PCO patients. Conclusion. Ovulatory PCO patients do not express similar endocrine abnormalities as PCOS patients. Although the fertilization rate and cleavage rate were relatively low in PCOS patients, ultimately, all the three groups showed similar transferred embryo numbers, clinical pregnancy rates, and implantation rates. Since the incidence of OHSS was much higher in the PCOS and ovulatory PCO patients, we should take more care of these patients and try to prevent severe OHSS.

Antinuclear antibodies predicts a poor IVF-ET outcome: impaired egg and embryo development and reduced pregnancy rate.

To investigate the impact of anti-nuclear antibodies (ANAs) on the outcome of in vitro fertilization-embryo transfer (IVF-ET), 66 (96 cycles) infertile women positive for anti-nuclear antibodies (ANA+ group), and 233(285 cycles) infertile women negative for ANAs (ANA- group) were enrolled. The clinical characteristics and IVF outcome were compared between the two groups. In the ANA+ group, the proportion of MII oocytes and two-pronuclear zygotes (2PN), cleavage rate, number of available embryos and proportion of available embryos, number of high-quality embryos and proportion of high-quality embryos were significantly lower than those in the ANA- group. In addition, the pregnancy rate and implantation rate in patients positive for ANA was markedly lower than the ANA- patients (28.1% vs 46.4%, 15% vs 25.7%, respectively). Thus, our findings suggest that the presence of ANAs significantly interfere with the oocyte and embryo development, as well as reduce implantation and pregnancy rate in patients undergoing IVF treatment.

Relationship between antithyroid antibody and pregnancy outcome following in vitro fertilization and embryo transfer.

OBJECTIVE: To investigate the impact of antithyroid antibody on pregnancy outcome following the in vitro fertilization and embryo transfer (IVF-ET). METHODS: A total of 90 patients (156 cycles) positive for antithyroid antibody (ATA+ group) and 676 infertile women (1062 cycles) negative for antithyroid antibody (ATA- group) undergoing IVF/ICSI from August 2009 to August 2010 were retrospectively analyzed. RESULTS: There was no significant difference in the days of ovarian stimulation, total gonadotropin dose, serum E2 level of HCG day and number of oocytes retrieved between the two groups. The fertilization rate, implantation rate and pregnancy rate following IVF-ET were significantly lower in women with antithyroid antibody than in control group (64.3% vs 74.6%, 17.8% vs 27.1% and 33.3% vs 46.7%, respectively), but the abortion rate was significantly higher in patients with antithyroid antibody (26.9% vs 11.8%). CONCLUSION: Patients with antithyroid antibody showed significantly lower fertilization rate, implantation rate and pregnancy rate and higher risk for abortion following IVF-ET when compared with those without antithyroid antibody. Thus, the presence of antithyroid antibody is detrimental for the pregnancy outcome following IVF-ET.

Impact of anticardiolipin antibody on the outcome of in vitro fertilization and embryo transfer.

PROBLEM: To investigate the impact of anticardiolipin antibody (ACA) on the outcome of in vitro fertilization and embryo transfer (IVF-ET). METHODS: A total of 76 infertile women positive for anticardiolipin antibody (ACA+ group) and 819 controls negative for anticardiolipin antibody (ACA- group) undergoing IVF-ET in the First Affiliated Hospital, to Sun Yat-Sen University, were retrospectively analyzed. Women were diagnosed as having pure tubal factor infertility. RESULTS: The proportion of patients with a history of spontaneous abortion in the ACA+ group was significantly higher than that in ACA- group (19.7% versus 8.9%). The IVF rate, pregnancy rate and implantation rate in the ACA+ group were markedly lower than those in the ACA- group (75.5% versus 78.9%, 31.3% versus 48.6% and 16.1% versus 28.1%, respectively). Furthermore, the incidence of pregnancy loss in the ACA+ group was higher than that in the ACA- group (32.0% versus 15.1%). CONCLUSION: ACA-positive patients had significantly decreased IVF rate, pregnancy rate and implantation rate and high risk of abortion. Therefore, ACA positivity predicts poor outcome of IVF-ET, and pre-treatment to lower ACA level may be clinically beneficial for patients receiving IVF-ET.

[Expression of soluble human leukocyte antigen G and its relationship to embryo development].

OBJECTIVE: To find out the expression of soluble human leukocyte antigen G (sHLA-G) and its relationship to the cleavage embryo development. METHODS: One hundred and seventy-seven day 3 cleavage embryos were detected for sHLA-G by immunohistochemistry. RESULTS: sHLA-G was detected in 57.1% cleavage embryos. The positive rate of sHLA-G in cleavage embryos developed from dipronucleate fertilized eggs was 66.2% (90/136), that developed from tripronucleate fertilized eggs was 26.8% (11/41). There was significant difference between these two groups (P < 0.01). The positive rate of sHLA-G in the grade 1 cleavage embryos developed from dipronucleate fertilized eggs was 64.3% (18/28), that in the grade 2 cleavage embryos developed from dipronucleate fertilized eggs was 91.7% (66/72), that in the grade 3 cleavage embryos developed from dipronucleate fertilized eggs was 16.7% (6/36), there were significant differences between these different embryo grades (P < 0.01), and the intensity of sHLA-G had negative relationship with the embryo grades (r = -0.503). The positive rate of sHLA-G in the first class cleavage embryos developed from tripronucleate fertilized eggs was 88.9% (32/36), that from dipronucleate fertilized eggs was 64.3% (18/28). There was significant difference in these two groups (P < 0.01). The intensity of sHLA-G in cleavage embryos developed from tripronucleate fertilized eggs was higher than that from dipronucleate fertilized eggs. The positive rate of sHLA-G in the cleavage embryos developed from dipronucleate fertilized eggs whose cell number was less than 4 was 56.7% (34/60), that from dipronucleate fertilized eggs whose cell number ranged from 5 to 6 was 67.9% (36/53), and that from dipronucleate fertilized eggs whose cell number ranged from 7 to 8 was 87.0% (20/23). There were no significant differences in these three groups. The intensity of sHLA-G had no significant difference between embryos with different cell number (P > 0.05), but it had relationship with the cell number (r = 0.267). CONCLUSION: Cleavage embryos express sHLA-G which is related with the embryo development.